Company intelligence / Profile preview
Ashvattha Therapeutics
Redwood City, California, USAlinkedin.com ↗
- Ownership
- Private
- Employees
- ~35
- Development stage
- Phase 2
01
Overview
Phase 2 data for subcutaneous migaldendranib (MGB) showed >69% reduction in anti-VEGF intravitreal treatment burden in study eyes and >67% reduction in fellow eyes of bilateral disease patients. The treatment was safe and well-tolerated with maintenance of BCVA and reduction of CST in previously treated patients. For subjects completing 24 weeks of treatment, there was a significant reduction in the need for supplemental intravitreal aflibercept.[5][6]
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- NanomedicineHydroxyl dendrimer therapeutics (HDTs)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Ashvattha Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ashvattha Therapeutics.